Research Article

Feyza Yağmur Tekeli*, Seçkin Özgür Tekeli and Özkan Köse

Serum vitamin D receptor and fibroblast growth factor-23 levels in postmenopausal primary knee osteoarthritis patients

https://doi.org/10.1515/tjb-2021-0293
Received December 21, 2021; accepted July 11, 2022; published online October 13, 2022

Abstract

Objectives: The role of vitamin D in primary osteoarthritis (OA) has not been clarified yet. vitamin D receptor (VDR) and fibroblast growth factor-23 (FGF-23) are proteins that play an important role in the metabolism of vitamin D. In this preliminary study, we aimed to examine serum 25-(OH) vitamin D3, VDR, and FGF-23 levels in primary knee OA patients.

Methods: This study includes 60 post-menopausal women who were enrolled into two groups with primary knee OA (n=30, age range between 59.6 ± 5.7 years) and control (n=30, age range between 61.7 ± 6.3 years). Serum levels of 25-(OH) vitamin D3 were measured by chemiluminescence and serum VDR, and FGF-23 were measured by enzyme-linked immunosorbent assay methods.

Results: In knee OA group, serum levels of 25-(OH) vitamin D3 were significantly lower (p=0.033), and serum VDR and FGF-23 levels were significantly higher than those of the control group respectively (p=0.000 and p=0.006). Also, FGF-23 levels showed correlations with 25-(OH) vitamin D3, VDR, and calcium levels (p<0.05).

Conclusions: This is the first study showing a relationship between serum VDR and FGF-23 in knee OA patients. Extensive clinical studies are required to assess the applicability of these parameters in clinical practice.

Keywords: aging; FGF-23; osteoarthritis; vitamin D; vitamin D receptor.

Introduction

Primary osteoarthritis (OA) is a musculoskeletal disease that causes chronic pain and disability [1]. It includes all elements of the joint and is characterised by the degeneration of the articular cartilage and subchondral bone [2]. Advancing age, previous history of injury, and obesity are shown among the most significant risk factors [3].

Mechanical, inflammatory, and metabolic factors play a role in its pathogenesis. In addition, it is a dynamic pathology caused by the imbalance between damage and repair processes in the joint rather than a passive degeneration [4]. Vitamin D has pivotal roles in bone and cartilage metabolism [5]. Vitamin D deficiency (VDD) is a worldwide health concern that can cause musculoskeletal problems [6]. Previously, many trials have been made to reveal the outcomes of VDD on the pathogenesis of OA. Although several studies show that VDD augments the incidence of OA [7, 8] and accelerates its progression [8–10], some studies do not support these findings [11, 12].

Vitamin D shows its effects on target tissues through vitamin D receptor (VDR). After calcitriol 1,25 (OH)2 vitamin D3 binds to VDR, it triggers two different cellular effects; genomic and non-genomic. In genomic (classical) effect calcitriol mostly binds to cytosolic VDR and then together translocate to the nucleus to exert its genomic effects. On the other hand in non-genomic effect, calcitriol binds to VDR which is associated with the plasma membrane caveolae to initiate cellular responses via rapid response pathways [13]. The active presence of VDR is shown in many tissues, involving bone, intestine, and kidney [14], as well as the cartilage tissue [15].

Studies have shown that the structure and content of matrix vesicles released from hypertrophic chondrocytes, which play an essential role in cartilage degeneration, are regulated by vitamin D [16, 17]. Clinical and experimental
studies demonstrated that vitamin D may be responsible for altered mineral ion hemostasis and increased matrix degradation observed in articular cartilage tissue with OA. These trials have substantiated that both VDR expression and the amount of protein increase in the joint cartilage tissue with OA [18, 19].

Fibroblast growth factor-23 (FGF-23) is a hormone that is secreted from osteocytes, primarily inhibits inorganic phosphate reabsorption in renal tubular epithelial cells and thus increases phosphate excretion [20]. FGF-23 also inhibits renal 1α-hydroxylase and activates 24-α hydroxylase, reducing the levels of calcitriol [21]. In turn, calcitriol stimulates FGF-23, a cartilage mineralization regulator, through VDR [19] and involves in endochondral ossification and chondrocyte hypertrophy in OA [22].

Thus, we hypothesized that both the VDR and the FGF-23 might have some regulatory roles in the pathogenesis of OA. This preliminary study examines both serum VDR and FGF-23 levels in individuals with or without knee OA.

Materials and methods

Patients and study design

This cross-sectional trial was undertaken in Antalya Research and Training Hospital between January and July 2018. The case group (Group I) consisted of subjects with primary knee OA, and the control group (Group II) encompasses patients who were selected among subjects without knee pain and OA. All participants were women, and Group I consisted of 30 outpatients (age range between 59.6 ± 5.7 years) who presented with daily knee pain for at least 3 months, the control group consisted of 30 outpatients (age range between 61.3 ± 6.3 years) with no complaints in the knee joint. Knee OA was evaluated regarding to the criteria established by the American College of Rheumatology (ACR) [23]. Kellgren–Lawrence radiological scoring system was applied to classify the severity of knee OA [24]. Patients with normal knee joint examination and no complaints of knee pain were included in the control group.

All participants in our study were postmenopausal and >50 years of age. The menopausal condition was characterized as the absence of menses for ≥1 year. Subjects with diseases that lead to secondary osteoporosis (Cushing’s syndrome, hyperthyroidism, hypogonadism, osteogenesis imperfecta, cirrhosis), inflammatory joint diseases, and those who had used vitamin D supplements in the last 6 months prior to blood collection were excluded from the study. Also, chronic diseases such as hypothyroidism, diabetes, chronic kidney or liver diseases, etc., were eliminated from the trial. All subjects were notified about the trial and informed written consent was received following the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee (Approval Number: 1/8, ID: 2018-007).

Biochemical parameters

Fasting blood samples were used to assess all biochemical parameters and erythrocyte sedimentation rate (ESR). Venous blood specimens to be used to analyze biochemical parameters were collected (between January and February 2018) in evacuated serum separator tubes (BD Vacutainer® SST™ II). These specimens were centrifuged at 1150 × g for 15 min at 4 °C for the analysis of ESR venous blood samples were collected in tubes with EDTA-K2 (Isothiuron green vac-tube®, Uni Lab, İstanbul, Türkiye). To analyze the serum samples in bulk for FGF-23 and VDR, we kept them frozen at ~80 °C. Other biochemical tests were assayed on the day of blood sampling. Blood urea nitrogen (enzymatic method), calcium (arsenazo III method), inorganic phosphorus (molybdenum blue method), magnesium (colorimetric, xylidyl blue assay), anti-streptolysin O (ASO) (taking turbidimetric), C-reactive protein (CRP) (immunoturbidimetric), rheumatoid factor (RF) (immunoturbidimetric) levels were examined with an analyzer (Beckman AU5800; Beckman Coulter Diagnostics, USA). Serum urea levels were calculated according to formula: Urea=U×BUN × 2.14. Serum 25-(OH) vitamin D3 and parathyroid hormone (PTH) concentrations were assayed by the chemiluminescence method (Access® Dx800; Beckman Coulter, Inc., CA, USA). The intra- and interassay coefficients of variation (CVs) for 25-(OH) vitamin D3 assay were 1.5–3.8% and 6.8–7.7% respectively. ESAs were assayed on VISION-C (Shenzhen YHLO Biotech Co., Shenzhen, China) ESR analyzer. Serum VDR and FGF-23 concentrations were analyzed by a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Sunred Biological Technology, Shanghai, China). The detection limits of the VDR and FGF-23 ELISA kits were 0.38 ng/mL and 9.38 pg/mL respectively. The intra- and interassay CVs for the VDR ELISA kit were 3.66–5.44% and 4.68–5.63% and for the FGF-23 ELISA kit were 4.56–6.51% and 4.36–5.62% respectively.

Statistical analysis

SPSS 18.0 (SPSS for Windows, Chicago, IL, USA) was used for all statistical analyses. The normality of data distribution was analyzed by the Kolmogorov–Smirnov test. Comparisons between groups were established by the Student’s t-test for normally distributed data (presented as mean ± standard deviation) and by the Mann–Whitney U-test for the non-normally distributed data (presented as medians [minimum–maximum]). The Chi-squared tests were used for the comparison of categorical variables in independent groups. We specified the Pearson or Spearman coefficients by correlation analysis. FGF-23 was used as a dependent variable for multiple linear regression analysis, and 25-(OH) vitamin D3, VDR, and calcium levels were used as independent variables. A value of p<0.05 was recognized as statistically significant.

Results

The mean age of the groups was 59.6 ± 5.7 years and 61.7 ± 6.3 years, respectively, for control and knee OA groups (p=0.276). Twenty-one of the OA group patients were classified as Grade III according to the Kellgren–Lawrence radiological scoring system classification and 9 as Grade IV. The demographic and biochemical characteristics of the participants were shown in Table 1. 25-(OH) vitamin D3 levels (ng/mL) were significantly lower in knee OA group than in control group (17.1±11.2 vs. 22.8±8.7, p=0.033) and also VDD prevalence were significantly higher in knee OA group than control group (p=0.018). There were no remarkable differences between the knee OA and control groups for age, phosphorus, parathormone, calcium, CRP, urea, magnesium, ASO, RF, and ESR levels.
Discussion

To the best of our knowledge, this inductive study is the first in the literature to show the serum concentrations of both FGF-23 and VDR in knee OA patients. Our results illustrated that 25-(OH) vitamin D3 levels were markedly lower, serum FGF-23 and VDR concentrations were markedly higher in knee OA group than those of the control group.

Many clinical studies have been undertaken to survey the association between knee OA and vitamin D in the literature. However, these studies revealed conflicting results which were interpreted in different ways. The Framingham Heart Study, which was performed on 556 participants over 4 years, showed that low 25-(OH) vitamin D3 did not affect knee OA incidence but related to an increased risk of progression of knee OA [10]. McAlindon et al. interpreted these results as that vitamin D does not play a remarkable role at the onset of knee OA pathogenesis; however, the bone tissue’s healthy response to damage to articular cartilage is an important predictor of OA progression [25].

Furthermore, in the Rotterdam study, 1,248 subjects were monitored throughout six and a half years for knee OA incidence and progression, and it was shown that low vitamin D levels increased knee OA incidence and accelerated its progression, especially in elderly patients with low bone mineral density [9]. In addition, it was also reported that improving the vitamin D status could prevent the development and progression of knee OA, particularly in the elderly.

In the study of Felson et al., where the results of two longitudinal studies were presented, it was reported that low suboptimal vitamin D levels did not affect knee OA incidence and progression [11]. In a cross-sectional study of 153 patients undergoing arthroplasty for knee OA, VDD prevalence was higher in the radiographic knee OA group [26]. In parallel with the findings of this study, the prevalence of VDD was observed to be higher in knee OA group in our study.

Joint is an organ that should be evaluated not only with cartilage, synovium, and subchondral bone but also with related ligaments, meniscus, periarticular muscles, and nerves (neuromuscular control system). Although OA is a pathology that is limited basically to the cartilage, synovium, and subchondral bone, other joint structures also play role in its etiopathogenesis. Factors, such as obesity, aging, and previous trauma, that disrupt the harmony of functional structures of an especially weight-bearing joint (e.g., obesity, aging, trauma etc.) lead to altered joint biomechanics and abnormal joint loading. In this manner, as a result of following microtraumas and inflammation, the process of OA begins [4, 27]. At this stage, we can mention the protective role

**Table 1**: Demographic and biochemical characteristics of the knee OA and control groups.

<table>
<thead>
<tr>
<th></th>
<th>Controls (n=30)</th>
<th>Knee OA (n=30)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (SD)</td>
<td>59.6 (±5.7)</td>
<td>61.7 (±6.3)</td>
<td>0.276</td>
</tr>
<tr>
<td>25-(OH) vitamin D3, ng/mL (SD)</td>
<td>22.8 (±8.7)</td>
<td>17.1 (±11.2)</td>
<td>0.033*</td>
</tr>
<tr>
<td>VDD prevalence, n (%)</td>
<td>13.0 (43.3)</td>
<td>22.0 (73.3)</td>
<td>0.018 b</td>
</tr>
<tr>
<td>VDR, ng/mL median (IQR)</td>
<td>0.47 (0.31–0.68)</td>
<td>1.23 (1.13–1.73)</td>
<td></td>
</tr>
<tr>
<td>FGF-23, pg/mL (SD)</td>
<td>85.4 (±19.9)</td>
<td>125.4 (±66.0)</td>
<td>0.007 b</td>
</tr>
<tr>
<td>Urea, mmol/L (SD)</td>
<td>5.33 (±1.44)</td>
<td>5.04 (±1.26)</td>
<td>0.451</td>
</tr>
<tr>
<td>Creatinine, mg/dL (SD)</td>
<td>0.82 (±0.11)</td>
<td>0.80 (±0.18)</td>
<td>0.536</td>
</tr>
<tr>
<td>Calcium, mg/dL (SD)</td>
<td>9.76 (±0.38)</td>
<td>9.88 (±0.61)</td>
<td>0.123</td>
</tr>
<tr>
<td>Magnesium, mg/dL median (IQR)</td>
<td>2.1 (±2.2)</td>
<td>2.1 (±2.2)</td>
<td>0.593</td>
</tr>
<tr>
<td>Phosphorus, mg/dL (SD)</td>
<td>3.8 (±0.4)</td>
<td>3.7 (±0.3)</td>
<td>0.317</td>
</tr>
<tr>
<td>ASO, IU (SD)</td>
<td>79.5 (±59.9)</td>
<td>77.9 (±67.3)</td>
<td>0.253</td>
</tr>
<tr>
<td>CRP, mg/L (SD)</td>
<td>4.12 (±3.43)</td>
<td>5.54 (±3.97)</td>
<td>0.282</td>
</tr>
<tr>
<td>RF, U/mL median (IQR)</td>
<td>6 (±6–10)</td>
<td>7 (±6–8)</td>
<td>0.669</td>
</tr>
<tr>
<td>PTH, pg/mL (SD)</td>
<td>48.6 (±16.2)</td>
<td>58.8 (±25.8)</td>
<td>0.074</td>
</tr>
<tr>
<td>ESR, mm/h (SD)</td>
<td>27.9 (±13.6)</td>
<td>21.3 (±9.6)</td>
<td>0.145</td>
</tr>
</tbody>
</table>

OA, osteoarthritis; VDD, vitamin D deficiency; VDR, vitamin D receptor; FGF-23, fibroblast growth factor-23; ASO, anti-streptolysin O; CRP, C-reactive protein; RF, rheumatoid factor; PTH, parathyroid hormone; ESR, erythrocyte sedimentation rate. Data are presented as n (%), mean (± standard deviation), median (IQR, interquartile range, 25th–75th percentile). *Statistically significant difference (p<0.05), bStatistically significant difference (p<0.01).
of vitamin D [25]. But in later stages, it seems that as a consequence of repetitive microtraumas and inflammation local and uncontrolled production of 1,25 (OH)₂ vitamin D₃ (will be discussed in the following paragraphs) leads to behavioral changes in chondrocytes; upregulation of matrix metalloproteinase production, reduction in proteoglycan synthesis [18, 19]. This means that imbalance towards the degradation of cartilage tissue. Studies have postulated that the release, structure, and content of matrix vesicles liberated from hypertrophic chondrocytes play crucial roles in the course of endochondral ossification, and all are regulated by vitamin D [16, 17]. Accordingly, it would be wiser to implement the higher prevalence of VDD in our patient group, as a tendency for knee OA in the past.

FGF-23 is one of the modulators of chondrocyte function, especially in maintenance of the specialized extracellular matrix [28, 29]. But in osteoarthritic cartilage increased FGF-23 makes its own contribution by causing chondrocyte hypertrophy and impaired mineralization [19, 22]. In our study, we have confirmed the findings of two previous studies that serum FGF-23 levels were increased in knee OA patients [30, 31]. FGF-23 is a phosphaturic hormone released from osteocytes in response to physiologically increased phosphorus, PTH and calcitriol levels [32, 33]. We did not find significant differences in serum PTH and phosphorus levels between knee OA and patient groups. Also, the positive correlation between serum FGF-23 and PTH levels in control group was lost in patient group and in both groups together. According to these results, it is reasonable to assume that 1,25 (OH)₂ vitamin D₃ is responsible for the increment of FGF-23 levels in knee OA patients. 1,25 (OH)₂ vitamin D₃ is one of the main regulators of FGF-23 expression and exerts its action on FGF-23 via binding to VDR [19]. Increased levels of the 1,25 (OH)₂ vitamin D₃ have been demonstrated in synovial fluids and cartilage tissues of patients with inflammatory arthritis. And it is believed that 1,25 (OH)₂ vitamin D₃ is synthesized in osteoarthritic synovial macrophages and hypertrophic chondrocytes by 1 alpha-hydroxylase rather than synthesized systemically [15, 18, 34, 35]. Animal and human chondrocyte studies showed that calcitriol triggered the release of FGF-23 [33, 34], and FGF-23 decreased calcitriol (by suppressing 25-hydroxyvitamin D-1α-hydroxylase and increasing 25-hydroxyvitamin D-24-hydroxylase) in a negative feedback loop [21]. Since 1,25 (OH)₂ vitamin D₃ synthesis in synovial fluid macrophages cannot be downregulated by FGF-23, cartilage tissue 1,25 (OH)₂ vitamin D₃ levels increase,
and by this way vitamin D signaling pathway is upregulated [36].

Besides FGF-23 we also have shown that serum VDR levels were higher in knee OA patients which may be attributed to increased vitamin D signalization. Orfanidou et al. showed that calcitriol increases FGF-23 levels through VDR [19]. The increase in VDR expression and VDR amount was also shown in tissue samples collected from knee OA joint cartilage and chondrocyte cultures [18]. However, it is pretty remarkable that VDR protein can be detected from simple blood samples taken from patients. In spite of there were very few studies that reported serum VDR levels in the literature [37, 38], apparently, VDR molecules can be detected in human serum samples and can show concentration differences between patient and control groups. From this fact, it can be said that VDR, associated with the plasma membrane caveolae, one that can be shed in blood like other measurable transmembrane proteins [39].

The regression model that we employed with significant independent variables (serum calcium, VDR, and 25-(OH) vitamin D3 levels) predicted only 21.9% variance of serum FGF-23. We believe that if we could add synovial fluid 1,25 (OH)2 vitamin D3 levels to our regression model as an independent variable, we might have a much stronger prediction. This was a limitation of our study. Furthermore, there are some other limitations of our study. This study included a small number of subjects, limiting the study’s statistical power. However, all patients were strictly selected according to ACR criteria. Another limitation of our study is that the control group does not have knee radiographs. However, as the researchers, we consider it ethically inappropriate for the control group who do not have any clinical findings in terms of knee OA to undergo knee radiography and be exposed to radiation.

Table 2: Multiple linear regression analysis model to assess the independent factors affecting FGF-23 (pg/mL).

<table>
<thead>
<tr>
<th></th>
<th>Beta (95% CI)</th>
<th>SE</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>VDR, ng/mL</td>
<td>14.98 (0.78–29.17)</td>
<td>7.08</td>
<td>0.039*</td>
</tr>
<tr>
<td>25-(OH) vitamin D3, ng/mL</td>
<td>-1.51 (-2.88–0.23)</td>
<td>0.68</td>
<td>0.030*</td>
</tr>
<tr>
<td>Calcium, mg/dL</td>
<td>30.14 (2.38–57.9)</td>
<td>13.85</td>
<td>0.034*</td>
</tr>
</tbody>
</table>

Dependent variable: FGF-23, Independent variables: VDR, 25-(OH) vitamin D3, calcium. Adjusting age, R²=0.219, p<0.05 was considered as statistically significant. FGF-23, fibroblast growth factor 23; VDR, vitamin D receptor; SE, standard error; IQR, interquartile range; CI, confidence interval. *Statistically significant difference (p<0.01).
The effect of vitamin D on target tissue depends on various factors such as, but not only, local calcitriol concentrations and VDR expression levels. For this reason, it would not be sufficient to investigate the effect of vitamin D on knee OA by only measuring 25-(OH) vitamin D₃ levels, particularly in large prospective cohort studies. We need parameters that can be measurable in blood and reflect vitamin D signalization sensitively and specifically. Our work can be described as a step taken in this direction.

**Research funding:** The present study was supported by the Scientific Research Projects Coordination Unit of Antalya Education and Research Hospital (Grant no: 81266704-869).

**Author contributions:** All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

**Competing interests:** Authors state no conflict of interest.

**Informed consent:** Informed consent was obtained from all individuals included in this study.

**Ethical approval:** The research related to human use has complied with all the relevant national regulations, institutional policies, and in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors' Institutional Review Board or equivalent committee (Antalya Research and Training Hospital Ethics Committee, 2018-007 1/8).

**References**


